The most common complaints were nausea (55% versus 12.6% with placebo), constipation (30.7% versus 11.6%), and vomiting (26.1% versus 4.1%)
It's engineered with a molecular modification that makes it far more resistant to degradation than natural GLP-1, giving it a half-life long enough for weekly injections
36 The causes of the initial acute pancreatitis episodes, before starting GLP-1 receptor agonist therapy, were idiopathic in 77 patients (48%), gallstones in 49 (30%), alcohol use in 21 (13%), hypertriglyceridemia in 9 (6%), and medication related in five (3%)
What they did: Obese mice received AOD-9604 orally (via gavage) for 14 days at various doses (50, 250, 500 g/kg)
These agonists/analogues of GLP-1 slow down gastric emptying, modulate calorie intake by increasing the sense of satiety, modulate cardiovascular activity, and regulate natriuresis at the renal level [6]
These materials are not for human consumption, veterinary use, diagnostic use, cosmetic use, therapeutic applications, or medical treatment